Imbria touts PhII success in hypertrophic cardiomyopathy, adding fuel to overall efficacy profile End Points, 07 Nov 2023 Imbria Pharmaceuticals’ partial fatty acid oxidation inhibitor improved outcomes in Phase II non-obstructive hypertrophic…